問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Others-

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation

Division of Others-

Division of Hematology & Oncology

更新時間：2023-09-19

黃彥霖
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

14Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃彥霖

List

20Cases

2020-01-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2020-01-06 - 2026-01-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2022-01-31 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2026-08-01 - 2031-08-31

Phase II

Not yet recruiting
Cancer immunotherapy research targeting mismatch repair deficiency (dMMR): Multimodal integrated analysis combining hyperpolarized dynamic magnetic resonance (DNP) and artificial intelligence.

  • Condition/Disease

    Newly diagnosed or recurrent gynecological cancers confirmed by histology, including ovarian cancer, cervical cancer, endometrial cancer and other gynecological cancers.

  • Test Drug

    Hyperpolarized [1-13C]Pyruvate

Participate Sites
1Sites

Not yet recruiting1Sites

2023-10-31 - 2027-12-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-11-01 - 2026-10-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites

2026-08-01 - 2030-02-28

Phase II

Not yet recruiting
A phase 2 open-label, randomized trial was conducted to evaluate the safety, efficacy, and optimal dosage of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.

  • Condition/Disease

    Head and neck squamous cell carcinoma

  • Test Drug

    Pembrolizumab Telisotuzumab Adizutecan

Participate Sites
5Sites

Not yet recruiting1Sites

2024-06-28 - 2028-05-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2024-06-28 - 2028-03-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB